Takeda to acquire GammaDelta Therapeutics

Sunday 14 November 2021

United Kingdom

Takeda Pharmaceutical Co Ltd is to acquire the cell therapy company GammaDelta Therapeutics Ltd, exercising an option that it obtained in 2017 from the UK company’s venture capital sponsor Abingworth LLP. Takeda is to make a pre-negotiated upfront payment for GammaDelta as well as potential development and regulatory milestone payments. In 2017, Takeda committed to invest up to $100 million in GammaDelta which included an equity investment.